Phibro Animal Health Q3 net sales up 32% to $347.8M; Adj EBITDA +85%; raises FY2025 guidance

PHIBRO ANIMAL HEALTH CORP

2025-Q3 EPS reported $0.76 vs consensus $0.64 ▲ beat (+19.7%)

Q3 net sales $347.8M (+32% YoY); net income $20.9M (+$12.5M); diluted EPS $0.51 (+$0.30).
Adjusted EBITDA $54.9M (+85% YoY); adjusted diluted EPS $0.63 (+$0.32).
Animal Health segment sales +42% driven by Zoetis MFA acquisition; legacy Animal Health flat.
Updated FY2025 guidance: net sales $1.26B-$1.29B, Adj EBITDA $177M-$183M (62% growth at midpoint).
Gross leverage ratio 3.0x; free cash flow $49.1M for trailing twelve months.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.